IN8BIO Inc., a clinical-stage biopharmaceutical company, announced that its INB-200 clinical trial for glioblastoma patients has demonstrated significant clinical progress. A patient in the trial has surpassed four years without progression, marking a notable milestone in the treatment of front-line, grade IV glioblastoma. The company presented these positive results at the ASCO 2025 Annual Meeting, where it was reported that patients receiving multiple doses of INB-200 achieved a median progression-free survival of 16.1 months, notably longer than the 6.9 months typically observed with the standard-of-care Stupp protocol. Additionally, 40% of these patients remained progression-free for over 18 months with no significant toxicities observed. These findings highlight the potential of INB-200 to extend overall survival and provide durable therapy for glioblastoma patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。